DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Nikos Pekiaridis - 1 AstraZeneca - 1 Susan Galbraith - 1
Top related locs:
U.K Swedish U.S radioconjugates
Top related orgs:
AstraZeneca - 2 Fusion Pharmaceuticals Inc - 2 Getty Images - 1 Pharmaceutical - 1 University of Oxford - 1 Covid - 1 World Health Organization - 1 European Union - 1

Search resuls for: "Fusion Pharmaceuticals Inc"


2 mentions found


☆ AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
  + stars: | 2024-05-08 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. Demand for the Vaxzevria vaccine has tailed off as new vaccines tailored to specific Covid variants have emerged, AstraZeneca said in a statement. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. Next to Covid vaccines, AstraZeneca has been working on a range of other treatments for illnesses including cancer.
Persons: Nikos Pekiaridis Organizations: AstraZeneca, Getty Images, Pharmaceutical, University of Oxford, Covid, World Health Organization, European Union, Fusion Pharmaceuticals Inc Locations: U.K
☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: +2 min
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
0 next >>
Total: 2